Prevalence and treatment of atherogenic dyslipidemia in the primary prevention of cardiovascular disease in Europe: EURIKA, a cross-sectional observational study

BMC Cardiovascular Disorders

Volumn 17, Issue 1, 2017, Pages

  Halcox, Julian P ^a   Banegas, José R ^b   Roy, Carine ^c   Dallongeville, Jean ^d   De Backer, Guy ^e   Guallar, Eliseo ^f   Perk, Joep ^g   Hajage, David ^c   Henriksson, Karin M ^h   Borghi, Claudio ⁱ  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c BICHAT HOSPITAL   (France)

^d UNIV LILLE   (France)

^e GHENT UNIVERSITY   (Belgium)

^f JOHNS HOPKINS UNIVERSITY   (United States)

^g LINNAEUS UNIVERSITY   (Sweden)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Atherogenic dyslipidemia; Cardiovascular disease; Epidemiology; Risk factors global assessment

Indexed keywords

ANTILIPEMIC AGENT; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; EUROPE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PROCEDURES; PROTOCOL COMPLIANCE; RISK FACTOR; STANDARDS; TREATMENT OUTCOME;

AGED; ATHEROSCLEROSIS; BIOMARKERS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; EUROPE; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PREVALENCE; PRIMARY PREVENTION; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 85027560648     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-017-0591-5     Document Type: Article

References (32)

1. European cardiovascular disease statistics http://www.ehnheart.org/cvd-statistics.html Accessed 18 Oct 2016
2. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL. European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-2381. 10.1093/eurheartj/ehw106
3. Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. ESC/EAS guidelines for the Management of Dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281-344
4. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet 2014; 384(9943): 626-635. 10.1016/S0140-6736(14)61177-6
5. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32(11): 1345-1361. 10.1093/eurheartj/ehr1123105250
6. Cooney MT, Dudina A, Bacquer D, Fitzgerald A, Conroy R, Sans S. How much does HDL cholesterol add to risk estimation? A report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil 2009; 16(3): 304-314. 10.1097/HJR.0b013e3283213140
7. Cooney MT, Dudina A, Bacquer D, Wilhelmsen L, Sans S, Menotti A. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009; 206(2): 611-616. 10.1016/j.atherosclerosis.2009.02.041
8. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350(14): 1387-1397. 10.1056/NEJMoa032804
9. Halcox JP, Roy C, Tubach F, Banegas JR, Dallongeville J, Backer G. C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMC Cardiovasc Disord 2014; 14: 25. 10.1186/1471-2261-14-253943833
10. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997; 95(1): 1-4. 10.1161/01.CIR.95.1.1
11. Banegas JR, Lopez-Garcia E, Dallongeville J, Guallar E, Halcox JP, Borghi C. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32(17): 2143-2152. 10.1093/eurheartj/ehr0803164103
12. Rodriguez-Artalejo F, Guallar E, Borghi C, Dallongeville J, Backer G, Halcox JP. Rationale and methods of the European study on cardiovascular risk prevention and Management in Daily Practice (EURIKA). BMC Public Health 2010; 10: 382. 10.1186/1471-2458-10-3822909167
13. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, Backer G. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24(11): 987-1003. 10.1016/S0195-668X(03)00114-3
14. Goff DC, Jr., Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Sr., Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129(25 Suppl. 2):S49-73
15. Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, Backer G. Survey of physicians' practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Cardiovasc Prev Rehabil 2011; 19(3): 541-550. 10.1177/1741826711407705
16. OneKey [http://www.i-marches.com/index.php?id=onekey]
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18(6): 499-502
18. HeartScore-a unique and interactive risk prediction and management system http://www.escardio.org/Education/Practice-Tools/CVD-prevention-toolbox/HeartScore. Accessed 18 Oct 2016
19. Halcox JP, Tubach F, Lopez-Garcia E, Backer G, Borghi C, Dallongeville J. Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe. PLoS One 2015; 10(2): e0115270. 10.1371/journal.pone.01152704333116
20. Chiang CE, Ferrieres J, Gotcheva NN, Raal FJ, Shehab A, Sung J. Suboptimal control of lipid levels: results from 29 countries participating in the Centralized pan-Regional Surveys on the Undertreatment of Hypercholesterolemia (CEPHEUS). J Atheroscler Thromb 2016; 23(5): 567-587. 10.5551/jat.31179
21. Schwandt P, Brady AJ. Achieving lipid goals in Europe: how large is the treatment gap?. Expert Rev Cardiovasc Ther 2004; 2(3): 431-449. 10.1586/14779072.2.3.431
22. Harchaoui KE, Visser ME, Kastelein JJ, Stroes ES, Dallinga-Thie GM. Triglycerides and cardiovascular risk. Curr Cardiol Rev 2009; 5(3): 216-222. 10.2174/1573403097889703152822144
23. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011; 123(20): 2292-2333. 10.1161/CIR.0b013e3182160726
24. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118(10): 993-1001. 10.1161/CIRCULATIONAHA.108.7773342574817
25. Ginsberg HN, Bonds DE, Lovato LC, Crouse JR, Elam MB, Linz PE. Evolution of the lipid trial protocol of the action to control cardiovascular risk in diabetes (ACCORD) trial. Am J Cardiol 2007; 99(12A): 56i-67i. 10.1016/j.amjcard.2007.03.024
26. Assmann G, Schulte H, Funke H, von Eckardstein A. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;(19 Supp. Mat):M8-14
27. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen male study. Circulation 1998; 97(11): 1029-1036. 10.1161/01.CIR.97.11.1029
28. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S. Triglycerides and the risk of coronary heart disease: 10, 158 incident cases among 262, 525 participants in 29 western prospective studies. Circulation 2007; 115(4): 450-458. 10.1161/CIRCULATIONAHA.106.637793
29. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298(3): 299-308. 10.1001/jama.298.3.299
30. Perk J, Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the fifth joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701. 10.1093/eurheartj/ehs092
31. Langlois MR, Delanghe JR, Buyzere M, Rietzschel E, Bacquer D. Unanswered questions in including HDL-cholesterol in the cardiovascular risk estimation. Is time still on our side?. Atherosclerosis 2013; 226(1): 296-298. 10.1016/j.atherosclerosis.2012.10.036
32. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139(10): 802-809. 10.7326/0003-4819-139-10-200311180-00007